Gopalan Narendran
Overview
Explore the profile of Gopalan Narendran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
528
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rosu L, Madan J, Tomeny E, Muniyandi M, Nidoi J, Girma M, et al.
Lancet Glob Health
. 2022 Dec;
11(2):e265-e277.
PMID: 36565704
Background: The STREAM stage 2 trial assessed two bedaquiline-containing regimens for rifampicin-resistant tuberculosis: a 9-month all-oral regimen and a 6-month regimen containing an injectable drug for the first 2 months....
2.
Goodall R, Meredith S, Nunn A, Bayissa A, Bhatnagar A, Bronson G, et al.
Lancet
. 2022 Nov;
400(10366):1858-1868.
PMID: 36368336
Background: The STREAM stage 1 trial showed that a 9-month regimen for the treatment of rifampicin-resistant tuberculosis was non-inferior to the 20-month 2011 WHO-recommended regimen. In STREAM stage 2, we...
3.
Esmail H, Narendran G, Nunn A
Indian J Med Res
. 2022 Sep;
155(3&4):325-328.
PMID: 36124505
No abstract available.
4.
Tiburcio R, Narendran G, Barreto-Duarte B, Queiroz A, Araujo-Pereira M, Anbalagan S, et al.
Front Immunol
. 2022 Apr;
13:873985.
PMID: 35432354
Background: Tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is a clinical aggravation of TB symptoms observed among a fraction of HIV coinfected patients shortly after the start of antiretroviral therapy (ART)....
5.
Narendran G, Jyotheeswaran K, Senguttuvan T, Vinhaes C, Santhanakrishnan R, Manoharan T, et al.
Int J Infect Dis
. 2020 Jul;
98:261-267.
PMID: 32623087
Objective: The influence of tuberculosis (TB)-immune reconstitution inflammatory syndrome (IRIS) on TB treatment outcomes and its risk factors were investigated among people with human immunodeficiency virus (HIV) and co-infected with...
6.
Narendran G, Oliveira-de-Souza D, Vinhaes C, Akrami K, Fukutani K, Banu K, et al.
BMC Infect Dis
. 2019 Jun;
19(1):529.
PMID: 31208430
Background: Tuberculosis (TB)-associated Immune reconstitution inflammatory syndrome (TB-IRIS) is an aberrant inflammatory response in TB patients with advanced human immunodeficiency virus coinfection, after antiretroviral therapy commencement. Case Presentation: We present...
7.
Silveira-Mattos P, Narendran G, Akrami K, Fukutani K, Anbalagan S, Nayak K, et al.
Sci Rep
. 2019 May;
9(1):8036.
PMID: 31123316
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.
8.
Natrajan M, Sridhar R, Narendran G, Ramachandran G, Kumar V, Tripathy S
Indian J Med Res
. 2019 May;
149(Suppl):S89-S93.
PMID: 31070184
No abstract available.
9.
Silveira-Mattos P, Narendran G, Akrami K, Fukutani K, Anbalagan S, Nayak K, et al.
Sci Rep
. 2019 Feb;
9(1):1502.
PMID: 30728405
Immune reconstitution inflammatory syndrome (IRIS) occurs in up to 40% of individuals co-infected with pulmonary tuberculosis (PTB) and HIV, primarily upon antiretroviral therapy (ART) initiation. Phenotypic changes in T-cells during...
10.
Fregonese F, Ahuja S, Akkerman O, Arakaki-Sanchez D, Ayakaka I, Baghaei P, et al.
Lancet Respir Med
. 2018 Mar;
6(4):265-275.
PMID: 29595509
Background: Isoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most common form of drug resistance, and is associated with failure, relapse, and acquired rifampicin resistance if treated with first-line anti-tuberculosis drugs. The...